Erschienen in:
11.06.2019 | Thoracic Oncology
Does a Lymph Node-Based Model Predict Clinical Value for Adjuvant Therapy in Squamous Cell Carcinoma of the Esophagus Treated With Upfront Surgery?
verfasst von:
Dana McCloskey, MD, David D. Shersher, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2019
Einloggen, um Zugang zu erhalten
Excerpt
The management of esophageal cancers is different outside the Western world, where the majority of esophageal cancer histology is squamous cell carcinoma (SCC) and many high-volume centers still use an esophagectomy-first approach. This differs from Western methodology, which is rooted in the landmark 2012 randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) trial, which demonstrated a clear difference in median overall survival of 49.4 versus 24.0 months between neoadjuvant chemoradiotherapy plus surgery and surgery only, respectively.
1 The safety and efficacy of the CROSS regimen led to its wide adoption in North America, with neoadjuvant chemoradiotherapy for all esophageal carcinomas and consideration of surgery as trimodality therapy for appropriate candidates. …